Estrogen Replacement Therapy in Postmenopausal Women

Primary Indication: Symptom Management, Not Disease Prevention

The U.S. Preventive Services Task Force explicitly recommends against routine use of estrogen (with or without progestin) for prevention of chronic conditions in postmenopausal women (Grade D recommendation) 3
Estrogen therapy is indicated primarily for managing vasomotor symptoms (hot flashes, night sweats) and genitourinary symptoms that significantly impact quality of life 4, 2
The harmful effects of estrogen therapy likely exceed chronic disease prevention benefits in most postmenopausal women, particularly those many years past menopause 1, 3

Women who initiate estrogen therapy more than 10 years after menopause face increased cardiovascular risks including stroke (8 additional strokes per 10,000 women-years) 2, 3
For women over 60 or more than 10 years postmenopausal, the risks substantially outweigh benefits for systemic therapy 2, 3

For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 7 additional coronary heart disease events 2
For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 8 additional strokes 2
For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 8 additional pulmonary emboli 1
For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 8 additional invasive breast cancers 2
For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 6 fewer colorectal cancers 2
For every 10,000 women taking estrogen-progestin therapy for 1 year, there are 5 fewer hip fractures 1

Women WITH an intact uterus must receive combined estrogen-progestin therapy to prevent endometrial cancer (reduces risk by approximately 90%) 2
Unopposed estrogen in women with a uterus increases endometrial cancer risk and is contraindicated 1

Transdermal estradiol patches should be first-line over oral formulations 2
Transdermal delivery avoids hepatic first-pass metabolism, resulting in more favorable cardiovascular and thrombotic risk profiles 2

Estrogen therapy is contraindicated in women with a history of breast cancer or other hormone-sensitive cancers 2
Estrogen therapy is contraindicated in women with coronary heart disease 2
Estrogen therapy is contraindicated in women with previous venous thromboembolic event or stroke 1
Estrogen therapy is contraindicated in women with active liver disease 2
Estrogen therapy is contraindicated in women with antiphospholipid syndrome or positive antiphospholipid antibodies 2

Never initiate estrogen therapy solely for osteoporosis or cardiovascular disease prevention without considering individual risk factors and alternative interventions 2, 3
Do not start systemic estrogen therapy in women over 65 for chronic disease prevention, as this increases morbidity and mortality 2
Avoid using systemic therapy when local vaginal estrogen would suffice for genitourinary symptoms alone 3
Do not fail to add progestin in women with intact uterus receiving estrogen therapy 2